Premium
Use of G‐CSF in Matched Sibling Donor Pediatric Allogeneic Transplantation: A Consensus Statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee
Author(s) -
Grupp Stephan A.,
Frangoul Haydar,
Wall Donna,
Pulsipher Michael A.,
Levine John E.,
Schultz Kirk R.
Publication year - 2006
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20800
Subject(s) - medicine , oncology , transplantation , stem cell , cog , sibling , gastroenterology , immunology , artificial intelligence , computer science , psychology , developmental psychology , genetics , biology
Preliminary studies indicate that G‐CSF‐primed marrow harvesting may result in a graft with increased mononuclear cells collected, increased CD34+ stem and progenitor cell dose and a potential for more rapid engraftment. Increased cell dose plus other potential positive effects of G‐CSF priming have resulted in improved survival in non‐randomized preliminary studies. These benefits may be available without the increased risk of chronic graft versus host disease (GVHD) that is experienced with allogeneic peripheral blood stem cell (PBSC) transplant. A phase III Children's Oncology Group (COG)/Pediatric Blood and Marrow Transplant Consortium (PBMTC) trial comparing G‐CSF‐primed marrow to standard marrow has been proposed. This document reviews background studies of G‐CSF‐primed marrow and addresses benefits and risks of G‐CSF administration to normal pediatric donors. We conclude that the approach is promising and warrants further study. Risks of G‐CSF to the donor are minimal and benefits to both donor and recipient may occur. Pediatr Blood Cancer 2006,46:414–421. © 2006 Wiley‐Liss, Inc.